Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet SyndromeApr 25, 2017 | Newshttps://www.newswire.com/news/epygenix-therapeutics-receives-orphan-drug-designation-from-the-u-s-19369643https://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-orphan-drug-designation-from-the-us-fda-for-epx-100-and-epx-200-in-the-treatment-of-patients-with-dravet-syndrome-300444990.html
